<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <link rel="shortcut icon" href="../figures/favicon.png" type="image/x-icon">
  <title>Carcinoma of the Endometrium</title>
  <link href="https://cdn.jsdelivr.net/npm/remixicon@2.5.0/fonts/remixicon.css" rel="stylesheet">
  <link rel="stylesheet" href="/style.css">
  <link rel="stylesheet" href="/notes.css">
</head>
<body>
  <input type="checkbox" id="main-navigation-toggle" class="btn btn--close" title="Toggle main navigation" />
  <label for="main-navigation-toggle">
    <span></span>
  </label>
  
  <a href="/index.html">
    <div class="home-navigation">
      M
    </div>
  </a>

  <nav id="main-navigation" class="nav-main">
    <ul class="menu">
      <li class="menu__item">
        <a class="menu__link" href="/index.html">Home</a>
      </li>
      <li class="menu__item">
        <a class="menu__link" href="/about-temp2.html">About</a>
      </li>
      
     
      

      <li class="menu__item">
        <a class="menu__link" href="#0">Projects</a>
        <ul class="submenu">
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Surgery</a>
          </li>
          <li class="menu__item">
            <a class="menu__link" href="/404.html">Pediatrics</a>
          </li>
        </ul>
      </li>
    </ul>
  </nav>
  
  <main class="page-container">
    <div class="contribute-cta">
      <p>Help make this betterüíú</p>
      <span><a href="/contribute.html">Contribute here</a> </span>
    </div>

    <h1>Carcinoma of the Endometrium</h1>
  
    <!-- <div class="author-flex">
      <div class="author-img">
        <img  src="/contributors/vt1.jpeg" alt="">
      </div>
      <div>
        <h2 class="name">Compiled by Victortayo</h2>
        <p class="updated">last updated, Nov 2022</p>
      </div>
    </div> -->

    <article class="notes">
        <a id='top'></a>
    <article>
    <!-- <h2 class='title'>Outline</h2> -->
    <label class="trigger outline">
        <input type="checkbox" class="checkbox checkbox--red" /> Show/hide outline
        <div class="msg">
         <ol>
            <li><a href="#header-1">Introduction</a></li>
            <li><a href="#header-2">Causes and risk factors</a></li>
            <li><a href="#header-3">Protective factors</a></li>
            <li><a href="#header-4">Clinical presentation</a></li>
            <li><a href="#header-5">Investigations</a></li>
            <li><a href="#header-6">Endometrial carcinoma precursors</a></li>
            <li><a href="#header-7">Staging of Endometrial Cancer</a></li>
            <li><a href="#header-8">Modalities of Treatment</a></li>
            <li><a href="#header-9">Prognostic Factors and Prognosis</a></li>
         </ol>
         
        </div>
      </label>

      <section id='header-1'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-1'>Introduction</a>
          </h2>
        </header>
        <div class='body'>
            <p>It is a malignant cancer of endometrial lining (epithelial lining)</p>
            <p>In developing countries it ranks third after cervix and ovaries </p>
            <p>In developed countries, where deaths from cervical cancer have been reduced by up to 50% because of screening, endometrial cancer ranks alongside ovarian cancer as the leading types of gynecological cancer.</p>

            <h4><span class="special-text-4">Incidence </span></h4>
            <p>Reported global cancer statistics show the incidence to be highest in North America, then Europe and temperate South America. </p>
            <p>The incidence of endometrial carcinoma is low in southern and eastern Asia, as well as in most of Africa.</p>
            <p>Ilorin: 10.7% </p>
            <p>Benin: 6.47% Okobia et al 2005</p>
            <p>Maiduguri: 8.5% Kyari et al 2004 </p>
            <p>Port Harcourt: 8.3% Briggs et al 1990</p>
            <p>Zimbabwe: 6% 1989</p>
        </div>

      </section>

      <section id='header-2'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-2'>Causes and risk factors</a>
          </h2>
        </header>
        <div class='body'>
            <p>Cause not known but there are known predisposing /risk factors</p>
            <p>NOTE that both major and minor risk factors have one common thread ‚Äìunopposed estrogen stimulation of the endometrium.</p>
            <h4>Obesity: </h4>
            <ul>
                <li>Major risk factor.</li>
                <li>Circulating androgens in the fatty tissue can be converted to estrone.</li>
                <li>Increase in free, unbound estrogen because SHBG which inactivates E2 is decreased.</li>
                <li>Upper body fat localization is a significant risk factor & have poorer prognosis.</li>
                <li>Associated with the other major risk factors like DM & hypertension.</li>
            </ul>

            <h4>Syndromes of increased endogenous estrogen stimulation:</h4>
            <ul>
                <li>Early menarche (4 fold increase especially in premenopausal women) & late menopause (menstruation span >39yrs have 4.2X increase than <25yrs).</li>
                <li>Infertility and low parity:</li>
                <ul>
                    <li>PCOS, probably due to long anovulatory cycles.</li>
                    <li>One-third of patients are nulliparous.</li>
                    <li>Risk decreases with increased parity.</li>
                </ul>
            </ul>

            <h4>Estrogen producing ovarian tumors:</h4>
            <ul>
                <li>Granulosa cell tumors.</li>
                <li>Theca cell tumors.</li>
            </ul>

            <h4>Familial and hereditary factors:</h4>
            <ul>
                <li>Familial adenocarcinoma syndrome (Lynch type II).</li>
                <li>Hereditary non poliposis colorectal cancer.</li>
            </ul>

            <h4>Life style factors:</h4>
            <ul>
                <li>Diet: animal fat & proteins increases risk. </li>
                <li>Sedentary life styles increases the risk. </li>
            </ul>

            <h4>Other factors:</h4>
            <ul>
                <li>Age is an important risk factor. It is a cancer of post & perimenopausal women.</li>
                <li>Race: White race have twice lifetime risk than black race. </li>
                <li>High social class.</li>
                The last 2 factors may be related to the availability of exogenous estrogen.
            </ul>

            <h4><span class="special-text-4">Exogenous estrogens: well established</span></h4>
            <p>Prolonged use of unopposed estrogen is associated with high risk of endometrial cancer.</p>
            <p>Stimulation of the endometrium occurs despite the route of administration. </p>
            <p>Increasing duration of use also increases the risk. The risk persists for many years after use.</p>
            <p>Risk also increases with increasing dose of conjugated estrogen.</p>
            <p>An increased incidence has also been found in association with tamoxifen treatment of breast cancer, perhaps related to the estrogenic effect of tamoxifen on the endometrium. </p>
            <p>The cancers associated with exogenous estrogen may behave biologically differently from their non-estrogen associated counterparts.</p>
            <p>Most estrogen induced tumors are of low virulence, well differentiated, with minimal myometrial invasion.</p>

        </div>
      </section>

      <section id='header-3'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-3'>Protective factors</a>
          </h2>
        </header>
        <div class='body'>
            <h4>The use of concomitant or cyclic progestins will greatly reduce the risk.</h4>
            <ul>
                <li>It inhibits the synthesis of both estrogen & progesterone receptors.</li>
                <li>Within the cell, it stimulates the 17-Œ≤-dehydrogenase enzyme that converts estradiol to the less potent estrone. </li>
                <li>In some women, moderately to poorly differentiated adenocarcinoma may develop despite the use of progestins.</li>
            </ul>

            <h4>Prior use of COCP reduces the risk.</h4>
            <ul>
                <li>Protection may be due to the net progestational effect that results in virtually inactive endometrium with long term use.</li>
                <li>The protection may last 20 or more years after discontinuation in long term users (10 or more years) but may be reversed by unopposed postmenopausal estrogen.</li>
            </ul>

            <h4>Life style factors</h4>
            <ul>
                <li>Smoking may have a protective effect probably due to the reduced circulating estrogen it induces.</li>
                <li>Active life style may be protective.</li>
                <li>Consumption of vegetables, fresh fruits & high fiber reduces the risk.</li>
                <li>Alcohol in moderate quantities may be protective.</li>
            </ul>
        </div>
      </section>

      <section id='header-4'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-4'>Clinical presentation</a>
          </h2>
        </header>
        <div class='body'>
            <p>The most common symptom is post-menopausal bleeding (75%) women usually in their 60s</p>
            <p>Bleeding may be slight, irregular or continuous</p>
            <p>In postmenopausal women any vaginal bleeding is considered to be from cancer until proven not to be.</p>
            <p>5-10% occur in women < 40yrs</p>
            <p>Some may have offensive vaginal discharge if there is infection.</p>
            <p>Pain may be colicky</p>
            <p>Few are asymptomatic</p>

            <h4><span class="special-text-4">Screening/Diagnosis</span></h4>
            <h4><span class="special-text-4b">Screening </span></h4>
            <ul>
                <li>Routine screening of women is not of any proven benefit. </li>
                <li>Occasionally, however, the Pap smear may fortuitously identify endometrial abnormalities.  </li>
            </ul>
            <h4><span class="special-text-4b"> Diagnosis</span></h4>
            <ul>
                <li>Detailed history and physical examination</li>
                <li>Help identify risk factors and associated medical conditions.</li>
            </ul>

            <h4><span class="special-text-4">Pattern of spread</span></h4>
            <p>Lymphatic spread via:</p>
            <ul>
                <li>Lymphatics from the infundibulopelvic ligament </li>
                <li>Paracervical & parametrial lymphatics</li>
                <li>Round ligament lymphatics to external iliac, obturator, hypogastric, common iliac and para-aortic.</li>
            </ul>
            <p>Direct spread into the peritoneal cavity</p>
            <p>Hematogenous to liver, lung, bone.</p>
        </div>
      </section>

      <section id='header-5'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-5'>Investigations</a>
          </h2>
        </header>
        <div class='body'>
            <h4><span class="special-text-4">Definitive diagnosis</span></h4>
            <ul>
                <li>Dilatation and (fractional) curettage</li>
                <li>Traditional 4 quadrant biopsy</li>
            </ul>

            <h4><span class="special-text-4">Other investigations</span></h4>
            <p>Other means of obtaining sample‚Äî lavage, brush or use of suction devices</p>
            <p>Hematological profile, E/U/Cr, LFTs, FBS</p>
            <p>USS abdo/pelvic.</p>
            <p>CT Scans, MRIs</p>
            <p>CXR</p>
            <p>Cystoscopy/sigmoidoscopy- if necessary</p>

        </div>
      </section>

      <section id='header-6'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-6'>Endometrial carcinoma precursors</a>
          </h2>
        </header>
        <div class='body'>
           <p><span class="special-text">Simple hyperplasia </span>(cystic hyperplasia). Risk of malignant potential/transformation is very low. </p>
           <p><span class="special-text">Complex hyperplasia</span> also called adenomyohyperplasia without atypia. Risk about 2% of either harboring or developing a malignancy within one year following that diagnosis. The risk is extremely low. </p>
           <p><span class="special-text">Atypical hyperplasia</span> also called adenomyohyperplasia with atypia carries a 15-25% risk. </p>

           <h4><span class="special-text-4"></span></h4>
            <ol>
                <li>Adenocarcinoma (well differentiated columnar cell with glandular pattern (90%)</li>
                <li>Adenocanthoma (adenocarcinoma with squamous metaplasia 5%)</li>
                <li>Adenosquamous carcinoma (mixed adenocarcinoma and squamous cell carcinoma)</li>
                <li>Anaplastic carcinoma- undifferentiated</li>
            </ol>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-7'>Staging of Endometrial Cancer </a>
          </h2>
        </header>
        <div class='body'>
           <p>The clinical staging adopted by FIGO in 1971 based on a standard uterine cavity length and extension of the disease beyond the uterus and pelvis.</p>
           <p>The FIGO Committee on Gynecologic Oncology, in 1988, recommended that endometrial cancer be surgically staged.</p>
           <ul>
            <li>Updated FIGO surgical staging 2009</li>
           </ul>

           <h4><span class="special-text-4"></span>Surgical Staging </h4>
           <h4><span class="special-text-4b"></span>Procedure</h4>
           <p>The procedure include:</p>
           <ul>
            <li>Peritoneal washings.</li>
            <li>TAH (simple) + BSO. </li>
            <ul>
                <li>If there is occult invasion outside the lower segment, the parametria is involved or the uterosacral ligaments are involved, a more radical operation may done.</li>
            </ul>
            <li>Lymph node sampling of all major node bearing areas, the ‚Äú10 lymphatic zones‚Äù.</li>
            <li>Laparoscopic staging may be done.</li>
           </ul>

           <h4><span class="special-text-4b">Histopathology ‚Äì degree of differentiation. </span></h4>
           <p> Cases of carcinoma of the corpus should be grouped with regard to the degree of differentiation of the adenocarcinoma as follows:</p>
           <ul>
            <li>G1: < 5% of a nonsquamous or nonmorular solid growth pattern.</li>
            <li>G2: 6-50% of a nonsquamous or nonmorular solid growth pattern.</li>
            <li>G3: > 50% of a nonsquamous or nonmorular solid growth pattern.</li>
           </ul>

           <h4><span class="special-text-4b">Surgical staging</span></h4>
           <ul>
            <li>I‚Äî Tumor confined to the corpus uteri</li>
            <ul>
                <li>IA: No invasion/Tumor invades < 1/2 myometrium </li>
                <li>IB: Tumor invades > 1/2 of myometrium </li>
            </ul>
            <li>II‚Äî  Tumor invades cervix </li>
            <li>III‚Äî  Local and/or regional spread </li>
            <ul>
                <li>IIIA: involves serosa and/or adnexa and/or +ve peritoneal washings.</li>
                <li>IIIB: Vaginal involvement.</li>
                <li>IIIC: pelvic / para-aortic lymph nodes (C1&2)</li>
            </ul>
            <li>IV‚Äî  Distance spread</li>
            <ul>
                <li>IVA: Tumor invades bladder mucosa and/or bower mucosa</li>
                <li>IVB: Distant metastasis including metastasis to intra-abdominal lymph nodes (other than para-aortic</li>
            </ul>
           </ul>
           


        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-8'>Modalities of treatment </a>
          </h2>
        </header>
        <div class='body'>
           <ul>
            <li>Surgical</li>
            <li>Radiotherapy</li>
            <li>Medical (chemo, hormonal)</li>
            <li>Palliative</li>
           </ul>

           <h4><span class="special-text-4">Clinical stage I</span></h4>
           <p>TAH, BSO. Routine node sampling not done, but any suspicious node is removed for histological evaluation. If there is deep myometrial involvement, sampling may be done.</p>
           <p>Consider post-operative radiation therapy, if deep myometrium involvement or G2, G3 </p>

           <h4><span class="special-text-4">Clinical stage II</span></h4>
           <p>Radical TAH, pelvic & para aortic node dissection, followed by irradiation.</p>
           <p>Primary irradiation (intracavitary & external beam) followed by surgery. May be done where there are technical problems e.g. extreme balooning of the cx</p>
           <p>Radiation alone in patients not medically fit for surgery</p>

           <h4><span class="special-text-4">Clinical stage III</span></h4>
           <p>Complete surgical resection where possible followed by extended field RT and/or systemic therapy with cytotoxic or hormones</p>
           <p>Preoperative pelvic irradiation followed by exploratory laparotomy. If good intracavitary radiation was delivered, a subtotal hysterectomy may be done to avoid bladder or bowel fistula.</p>

           <h4><span class="special-text-4">Clinical stage IV</span></h4>
           <p>Optimal cytoreduction followed by systemic chemotherapy.</p>
           <p>High doses of progestins may be used especially in distant metastasis and include hydroxy-progesterone (Delalutin), medroxy-progesterone (Provera), and megestrol (Megace). </p>
           <p>Pelvic RT may be given to achieve local control & prevent bleeding. Local RT in the brain or bone may be useful.</p>
           <p>Primary radiotherapy is in indicated in:</p>
           <ul>
            <li>Unfit for surgery</li>
            <li>Inoperable disease</li>
            <li>Palliation in advanced disease</li>
            <li>High risk for recurrence</li>
           </ul>
           <p>Chemotherapy used in advanced and recurrent dis.</p>
           <p>Progestogens: well differentiated disease with estrogen and progesterone receptors. Medroxyprogesterone, megestrol acetate in high doses</p>
           <p>Cytotoxics: adriamycin,cyclophosphomide, cisplatin paclitaxel singly or in combination</p>
        </div>
      </section>

      <section id='header-7'>
        <header>
          <h2>
            <a aria-hidden='true' href='#header-9'>Prognostic factors and Prognosis </a>
          </h2>
        </header>
        <div class='body'>

            <h4><span class="special-text-4">Prognostic factors</span></h4>

           <p>Histological grade (Tumor grade 3):</p>
           <ul>
            <li>Decrease survival</li>
            <li>Increased risk of lymph node involvement</li>
            <li>Increased risk of recurrence  </li>
           </ul>
           <p>Deep myometrial invasion: Most reliable indicator of tumor volume</p>
           <p>Lymph vascular channel involvement</p>
           <p>Positive peritoneal cytology</p>
           <p>Histologic type</p>
           <ul>
            <li>Serous papillary & Clear cell tumours</li>
           </ul>
           <p>Cervical involvement (stage II)</p>
           <p>Adnexal spread</p>
           <p>Intraperitoneal disease</p>
           <p>Increasing age</p>
           <p>Steroid receptors:</p>
           <ul>
            <li>Most endometroid ca have ER & PR.</li>
            <li>The presence & quantity of the receptors correlate with the histologic differentiation, FIGO staging & survival.</li>
            <li>High levels found in well differentiated tumors & ass with better survival rates.</li>
            <li>Receptor status influence tumor response to progestin therapy.</li>
           </ul>

           <h4><span class="special-text-4">Prognosis</span></h4>
           <p>Overall 5year survival rate:</p>
           <ul>
            <li>Stage I: 80% up to 95% reported.</li>
            <li>Stage II: 60%</li>
            <li>Stage III: 30%</li>
            <li>Stage IV: 5%</li>
           </ul>

        </div>
      </section>

      </section>

      <div class="contact">
        <hr style="margin: 3rem 0;">

        <p>Send us a <a href="mailto:obgyn.materia@gmail.com"><span class="special-text-2">mail</span></a> at 
         <br> obgyn.materia@gmail.com.</p>
        <p>Or send your comments, corrections, explanations/clarifications and requests/suggestions to our 
         <br> <a href="" class="special-text-2" style="text-decoration: none;">WhatsApp group</a>.</p>
      </div>
    </article>
   </article>
   <div style="height: 300px;"></div>
  </main>

  <footer>
    <div class="footer-container">
        <div>
          <p>obgyn.materia</p>
          
        </div>
    </div>
  </footer>
<!------------  SCROLL UP ----------->
<a href="#" class="scrollup" id="scroll-up"> 
  <i class="ri-arrow-up-fill scrollup__icon"></i>
</a>
<script src="/main.js"></script>
</body>
</html>
 
